Suppliers and packagers for generic pharmaceutical drug: NEDOSIRAN SODIUM

NEDOSIRAN SODIUM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novo	RIVFLOZA	nedosiran sodium	SOLUTION;INJECTION	215842	NDA	Novo Nordisk	0169-5306-10	1 SYRINGE in 1 CARTON (0169-5306-10) / 1 mL in 1 SYRINGE	2024-02-19
Novo	RIVFLOZA	nedosiran sodium	SOLUTION;INJECTION	215842	NDA	Novo Nordisk	0169-5307-08	1 SYRINGE in 1 CARTON (0169-5307-08) / .8 mL in 1 SYRINGE	2024-02-19
Novo	RIVFLOZA	nedosiran sodium	SOLUTION;INJECTION	215842	NDA	Novo Nordisk	0169-5308-01	1 VIAL in 1 CARTON (0169-5308-01) / .5 mL in 1 VIAL	2024-02-19

Suppliers for the Pharmaceutical Drug: Nedosiran Sodium

Last updated: July 30, 2025

Introduction

Nedosiran sodium, a promising nucleic acid-based therapeutic, has garnered attention due to its potential in treating hereditary and rare metabolic disorders, particularly primary hyperoxaluria. As a specialized pharmaceutical product, its sourcing involves a limited and structured supply chain, primarily centered around innovative biopharmaceutical companies and contract manufacturing organizations (CMOs). This report offers a comprehensive overview of current suppliers involved in the production, distribution, and development of nedosiran sodium, providing vital insights for industry stakeholders, investors, and healthcare providers.

Overview of Nedosiran Sodium

Nedosiran sodium is a small interfering RNA (siRNA) therapeutic designed to target hepatic lactate dehydrogenase A (LDHA) to reduce oxalate production. Developed by Alnylam Pharmaceuticals, this compound marks a significant advancement in RNA interference (RNAi) therapeutics, emphasizing the importance of a secure supply chain given its complex manufacturing process that relies on specific raw materials, delivery systems, and stringent quality controls.

Key Suppliers in Nedosiran Sodium Supply Chain

1. Active Pharmaceutical Ingredient (API) Manufacturers

The production of nedosiran sodium hinges on the synthesis of high-quality siRNA molecules, which are complex and require specialized manufacturing capabilities.

• Alnylam Pharmaceuticals
  As the pioneer and developer of nedosiran sodium, Alnylam is the primary overseer of the drug’s development and manufacturing pathway. The company either in-house synthesizes parts of the API or collaborates with specialized contract manufacturers. Their manufacturing facilities are certified under Good Manufacturing Practice (GMP), ensuring compliance with global standards.

• Contract Manufacturing Organizations (CMOs)
  Alnylam partners with multiple CMOs globally to produce the siRNA API. These include:

  • BioSpring GmbH (Germany): Specializes in synthesizing oligonucleotides, including siRNA molecules, using proprietary phosphoramidite chemistry.
  • Alnylam’s internal facilities are reported to handle critical steps involving synthesis, purification, and formulation, given the sensitivity of the product to degradation.

2. Lipid Nanoparticle (LNP) Formulation Suppliers

Delivery systems are crucial for the stability and targeted delivery of nedosiran sodium.

• Acuitas Therapeutics (Canada):
  A leading provider of LNP delivery systems used in RNA therapeutics, Acuitas supplies the lipid components necessary for effective delivery of siRNA molecules into hepatic cells.

• CordenPharma (Switzerland):
  Provides lipid components and encapsulation services compliant with GMP standards, facilitating the formulation of the final product.

3. Raw Material Suppliers

Nedosiran sodium production demands high-purity raw materials, including phosphoramidites, nucleoside triphosphates, and specialized solvents.

• Sigma-Aldrich (Merck Group) (USA/Germany):
  Supplies phosphoramidite reagents, nucleotides, and solvents crucial for oligonucleotide synthesis, including custom modifications specific to nedosiran.

• Thermo Fisher Scientific:
  Acts as a secondary supplier for required chemicals and purification reagents.

4. Packaging and Distribution

Secure packaging and cold chain logistics are fundamental due to the drug's sensitivity.

• World Courier:
  Provides specialized logistics services for temperature-controlled transportation, ensuring integrity throughout distribution.

• Schott AG (Germany):
  Manufactures specialized vials and syringes suitable for biologic storage and administration.

Manufacturing Challenges and the Role of Suppliers

Producing nedosiran sodium involves multiple complex steps, including oligonucleotide synthesis, lipid nanoparticle formulation, and sterile filling. Suppliers must meet stringent regulatory standards, including GMP compliance, batch-to-batch consistency, and traceability.

The reliance on select CMOs and raw material providers underscores the importance of supply chain resilience. Any disruption can delay clinical trials, impact regulatory approval timelines, and affect market availability.

Emerging Suppliers and Strategic Partnerships

Alnylam’s strategic collaborations with suppliers like BioSpring and Acuitas are vital to ensure scalability and robustness of the supply chain. Emerging suppliers are exploring innovations in oligonucleotide synthesis and delivery systems, potentially diversifying the supplier base and mitigating risks associated with supply restrictions.

Interest from biotech startups and CMOs indicates ongoing development efforts, emphasizing the need for diversified sourcing to meet anticipated demand.

Regulatory and Quality Assurance

Suppliers must adhere to rigorous regulatory standards set by agencies such as the FDA, EMA, and PMDA. Continuous quality assurance measures, validation protocols, and supply chain audits are integral to maintaining compliance and ensuring patient safety.

Conclusion

The supply chain for nedosiran sodium is characterized by a limited network of highly specialized suppliers, primarily led by Alnylam Pharmaceuticals along with key CMOs for oligonucleotide synthesis and delivery systems. Raw material providers supply critical nucleic acid components, while logistics companies ensure the integrity of cold chain distribution. As demand grows, diversification of suppliers and strengthening of manufacturing partnerships remain essential to secure an uninterrupted supply of this innovative therapy.

---

Key Takeaways

• Strategic partnerships with CMOs like BioSpring and Acuitas are central to nedosiran sodium’s supply chain, ensuring high-quality manufacturing and formulation.
• Raw material providers such as Sigma-Aldrich and Thermo Fisher Scientific supply critical reagents necessary for oligonucleotide synthesis, with emphasis on purity and batch consistency.
• Delivery and distribution partners like World Courier and Schott AG ensure product stability and integrity during global logistics, vital for maintaining efficacy.
• Supply chain resilience hinges on diversification of suppliers and compliance with regulatory standards to mitigate risks associated with manufacturing disruptions.
• Ongoing innovation and industry collaborations are likely to expand the supplier network, supporting larger-scale production as nedosiran sodium gains market approval.

---

FAQs

1. Who are the primary suppliers involved in manufacturing nedosiran sodium?
Alnylam Pharmaceuticals oversees the manufacturing process, partnering with specialized CMOs such as BioSpring for oligonucleotide synthesis and Acuitas Therapeutics for lipid nanoparticle formulation.

2. What raw materials are critical for neodiran sodium production?
High-purity phosphoramidites, nucleoside triphosphates, solvents, and lipids are essential raw materials supplied by vendors like Sigma-Aldrich and Thermo Fisher Scientific.

3. How do supply chain disruptions impact nedosiran sodium availability?
Disruptions in raw material supply, manufacturing capacity, or logistics can delay clinical trials and commercialization, emphasizing the need for diversified and resilient supplier networks.

4. Are there emerging suppliers for nedosiran sodium components?
Yes, biotech firms and CMOs are investing in new synthesis techniques and delivery technologies, potentially broadening the supplier base and enhancing manufacturing capacity.

5. What regulatory considerations apply to suppliers of nedosiran sodium?
Suppliers must adhere to GMP standards, implement rigorous quality controls, and maintain compliance with FDA, EMA, and other regulatory bodies to ensure product safety and efficacy.

---

References

1. [1] Alnylam Pharmaceuticals. “Nedosiran Overview,” 2023.
2. [2] BioSpring GmbH. “Oligonucleotide manufacturing capabilities,” 2022.
3. [3] Acuitas Therapeutics. “Lipid nanoparticle delivery systems,” 2023.
4. [4] Sigma-Aldrich. “Specialized Reagents for Oligonucleotide Synthesis,” 2022.
5. [5] World Courier. “Cold chain logistics for biologics,” 2023.